Neither
the purchase nor the distribution of pharmaceuticals in hospitals
and community pharmacies in Mexico is under the care of pharmacists.
Some are under control of physicians.
This report presents the results of the implementation of somef
pharmaceutical services for the Jalisco Pain Relief, and Palliative
Care Institute (Palia Institute), under the direction of the Secretary
of Health, Government of Jalisco. The services implemented were
drug distribution system, Drug Information Service, Pharmacovigilance
Program , and home pharmacotherapy follow-up pilot program for
patients with advanced illness, with the ultimate using the appropriate
medication. The drug distribution system included dispensing of
opioid pain medications, antidepressants, anticonvulsants, NSAIDs,
anxiolytic drugs, steroid drugs, laxatives, and anti-emetics.
The frequently used drugs were morphine sulfate (62%), amitriptyline
(6.4%), and dextropropoxyphene (5.8%). The Drug Information Service
answered 114 consultations, mainly asked by a physician (71%)
concerned with adverse drug reactions and contraindications (21%).
The pharmacovigilance program identified 146 suspected adverse
drug reactions and classified them reasonably as possible (27%),
probable (69%), and certain (4%). These were attributed mainly
to pregabalin and tramadol. The home pharmacotherapy follow-up
pilot program cared patients with different cancer diagnoses and
drug-related problems (DRP), which were identified and classified
(according to second Granada Consensus) for pharmaceutical intervention
as DRP 1 (5%), DRP 2 (10%), DRP 3 (14%), DRP 4 (19%), DRP 5 (24%),
or DRP 6 (28%).
This report provides information concerning the accurate use of
medication and, above all, an opportunity for Mexican pharmacists
to become an part of health teams seeking to resolve drug-related
problems.
|
|
